Factors Associated with Response to Acetylcholinesterase Inhibition in Dementia: A Cohort Study from a Secondary Mental Health Care Case Register in London
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Acetylcholinesterase inhibitors (AChEIs) are widely used to delay cognitive decline in Alzheimer's disease. Observational studies in routine clinical practice have shown cognitive improvement in some groups of patients receiving these agents but longitudinal trajectories before and after AChEI initiation have not previously been considered. OBJECTIVES: To compare trajectories of cognitive function before and after AChEI initiation and investigate predictors of these differences. METHOD: A retrospective longitudinal study was constructed using data from 2460 patients who received AChEIs and who had routine data on cognitive function (Mini-Mental State Examination; MMSE) before and after AChEI initiation. Longitudinal MMSE change was modelled using three-piece linear mixed models with the following segments: 0-12 months prior to AChEI initiation, 0-6 months and 6-36 months after initiation. RESULTS: MMSE decline was reversed (in that the slope was improved by an average 4.2 units per year, 95% CI 3.5-4.8) during the 6-month period following AChEI initiation compared with the slope in the one year period before AChEI initiation. The slope in the period from 6-36 months following AChEI initiation returned to the pre-initiation downward trajectory. The differences in slopes in the 1 year period prior to AChEI initiation and in the 6 months after initiation were smaller among those with higher MMSE scores at the time of AChEI initiation, among those who received a vascular dementia diagnosis at any point, and among those receiving antipsychotic agents. CONCLUSION: In this naturalistic observational study, changes in cognitive trajectories around AChEI initiation were similar to those reported in randomised controlled trials. The magnitude of the difference in slopes between the 1 year period prior to AChEI initiation and the 6 month period after AChEI initiation was related to level of cognitive function at treatment initiation, vascular comorbidity and antipsychotic use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Generalized additive models for location, scale and shape.
Rigby, R. A., & Stasinopoulos, D. M. (2005) · Journal of the Royal Statistical Society Series C: Applied Statistics · doi:10.1111/j.1467-9876.2005.00510.x · Cited by 3,228 · cited 1×
“The trajectory of MMSE scores in the sample was initially modelled for observational purposes using a non-parametric regression method: the Generalised Additive Model for Location, Scale and Shape (GAMLSS) introduced by Rigby and Stasinopoulos [8].”
MethodDonepezil for dementia due to Alzheimer’s disease.
Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200
Chang, C.-K., Hayes, R. D., Perera, G., Broadbent, M. T. M., Fernandes, A. C., Lee, W. E., Hotopf, M., & Stewart, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019590 · Cited by 714
Self-citationStewart, R., Soremekun, M., Perera, G., Broadbent, M., Callard, F., Denis, M., Hotopf, M., Thornicroft, G., & Lovestone, S. (2009) · BMC Psychiatry · doi:10.1186/1471-244x-9-51 · Cited by 445
Self-citationAdelman, S., Blanchard, M., Rait, G., Leavey, G., & Livingston, G. (2011) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.086405 · Cited by 87
Wallin, Å. K., Andreasen, N., Eriksson, S., Båtsman, S., Näsman, B., Ekdahl, A., Kilander, L., Grut, M., Rydén, M., Wallin, A., et al. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000098052 · Cited by 84 · cited 1×
“However, another study found no change over 6 months in people receiving donepezil [10], a finding that concurred with other studies of donepezil in clinical practice over the same period [11], suggesting stabilisation of cognitive decline rather than improvement over the first 6 months.”
ResultWallin, Å. K., Gustafson, L., Sjögren, M., Wattmo, C., & Minthon, L. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000079201 · Cited by 45
Cited by
Perera, G., Broadbent, M., Callard, F., Chang, C.-K., Downs, J., Dutta, R., Fernandes, A., Hayes, R. D., Henderson, M., Jackson, R., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-008721 · Cited by 492
Self-citationSharma, S., Mueller, C., Stewart, R., Veronese, N., Vancampfort, D., Koyanagi, A., Lamb, S. E., Perera, G., & Stubbs, B. (2018) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2018.03.009 · Cited by 72
Self-citationPredictors of response to acetylcholinesterase inhibitors in dementia: A systematic review
Pozzi, F. E., Conti, E., Appollonio, I., Ferrarese, C., & Tremolizzo, L. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.998224 · Cited by 36
Sommerlad, A., Werbeloff, N., Perera, G., Smith, T., Costello, H., Mueller, C., Kormilitzin, A., Broadbent, M., Nevado‐Holgado, A., Lovestone, S., et al. (2022) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5625 · Cited by 14
“The people in each of the three drug groups showed an initial improvement from the first to second assessment and this is consistent with other naturalistic studies examining cognitive function in routine practice.(16) This improvement may reflect the combined effect of simultaneous initiation of pharmacological or ps…”
ResultSelf-citation
Metadata
- Authors
- Perera, G., Khondoker, M., Broadbent, M., Breen, G., & Stewart, R.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-11-20
- Volume
- 9
- Issue
- 11
- Pages
- e109484
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1981486964
- Cited by
- 67
- References
- 8
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.